ERBB2 and breast cancer: Breast cancer is traditionally considered as poorly immunogenic, but the TNBC and HER2-positive subtypes show a high level of TIL, indicating that an immunotherapeutic approach may be suitable for this hard-to-treat malignancy [104,105].